On January 16, 2024 Accurus Biosciences Inc. ("Accurus") reported that it has entered into a worldwide licensing agreement for its CLDN18.2 monoclonal antibody with ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company focusing on the development of next generation chimeric antigen receptor (CAR) T-cell therapies (Press release, Accurus Biosciences, JAN 16, 2024, View Source [SID1234639282]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to announce that ImmPACT Bio chose to utilize our potential best-in-class CLDN18.2 antibody to develop next generation CAR T therapies," said Dr. Richard Zhang, chief executive officer of Accurus. "We believe ImmPACT’s programs have the potential to deliver differentiated and powerful therapies to benefit cancer patients."

Under the terms of the agreement, Accurus Biosciences has granted exclusive worldwide rights to ImmPACT Bio to develop and commercialize next generation cell therapies using a designated antibody from Accurus’ CLDN18.2 antibody portfolio. Accurus retains the rights to develop and commercialize its CLDN18.2 antibody portfolio for all non-cell based therapeutic applications. The financial terms were not disclosed